Si prevede che il mercato dei radiofarmaci raggiungerà i 13.818,17 milioni di dollari entro il 2028 rispetto ai 7.550,74 milioni di dollari del 2021; si prevede che crescerà a un CAGR del 9,0% dal 2021 al 2028.
La crescita del mercato è attribuita alla crescente prevalenza di malattie croniche, all'idoneità della radioimmunoterapia alfa in terapie mirate trattamento del cancro e progressi nelle tecniche di imaging nucleare. Tuttavia, la breve durata di conservazione dei radiofarmaci e la disponibilità di sostituti frenano la crescita del mercato dei radiofarmaci. Un radiofarmaco è un farmaco che può essere utilizzato sia a scopo diagnostico che terapeutico. I radiofarmaci sono radioisotopi legati a molecole biologiche che colpiscono specifici tessuti, organi o cellule del corpo umano. I radioisotopi che emettono raggi gamma sono utili per l'imaging diagnostico in cui la radiazione sfugge al corpo. Questi raggi vengono rilevati da un dispositivo specifico, che di solito è una telecamera per tomografia computerizzata a emissione di fotone singolo (SPECT)/tomografia a emissione di positroni (PET).
La pandemia di COVID-19 ha profondamente cambiato le attività ospedaliere, comprese quelle nucleari. pratiche mediche (NM) in tutta Europa. È stata effettuata una ricerca bibliografica su PubMed riguardante gli studi sul COVID-19 pubblicati fino a gennaio 2021. Secondo i risultati, la pandemia ha messo a dura prova i dipartimenti di MN e una riduzione della forza lavoro è stata riscontrata in ogni centro in Europa. Per limitare la trasmissione del COVID-19, i dipartimenti del Nuovo Messico hanno introdotto misure di restrizione, come la riprogrammazione delle procedure non ad alta priorità. Inoltre, alcuni reparti hanno subito ritardi nella fornitura di radiofarmaci o nell’assistenza tecnica a causa della pandemia. Di conseguenza, la crisi ha comportato una significativa riduzione delle procedure diagnostiche e terapeutiche della MN e un ridotto livello di assistenza per i pazienti affetti da malattie, come il cancro o le malattie cardiovascolari acute.
Regioni redditizie per il mercato dei radiofarmaci< br>Approfondimenti di mercato
L'aumento della prevalenza delle malattie croniche alimenta la crescita del mercato dei radiofarmaci
La prevalenza di malattie croniche come le malattie cardiovascolari (CVD), cancro, malattie polmonari croniche, ictus, morbo di Alzheimer, malattia renale cronica e diversi disturbi neurologici stanno aumentando rapidamente in tutto il mondo. Queste malattie sono tra le principali cause di morte. Secondo l’Organizzazione Mondiale della Sanità (OMS), nel 2020 il cancro ha causato 10 milioni di decessi a livello globale. Inoltre, secondo le stime dell’American Cancer Society, nel 2020 negli Stati Uniti sono stati diagnosticati 1.806.590 nuovi casi di cancro. Secondo l’European Heart Network, le malattie cardiovascolari causano 3,9 milioni di decessi in Europa e oltre 1,8 milioni di decessi nell’Unione Europea ( UE) ogni anno. Rappresentano il 45,0% della mortalità totale in Europa e il 37,0% del conteggio totale delle morti nell’UE. Secondo l’American College of Cardiology, le malattie cardiovascolari causano ogni anno 800.000 casi di morte negli Stati Uniti. La malattia coronarica (CHD) contribuisce alla maggior parte delle mortalità per malattie cardiovascolari, seguita da ictus e insufficienza cardiaca; Ogni anno a 90 milioni di americani vengono diagnosticate malattie cardiovascolari. Inoltre, le malattie cardiovascolari contribuiscono al 31% del totale dei decessi a livello globale e si prevede che il costo delle malattie cardiovascolari sui sistemi sanitari ammonterà a 1.044 miliardi di dollari entro il 2030.
Secondo Emory Healthcare, nel 2018, 5 milioni le persone soffrono di insufficienza cardiaca congestizia (CHF) negli Stati Uniti. Inoltre, secondo l’OMS, circa 1,71 miliardi di persone nel mondo soffrono di patologie muscolo-scheletriche. Per il trattamento delle malattie croniche è necessario un esame efficace e le sostanze nucleari vengono utilizzate a fini diagnostici ed esaminativi; sono utilizzati in test diagnostici come la tomografia a emissione di positroni (PET) e la tomografia computerizzata a emissione di fotone singolo (SPECT). Pertanto, con l'aumento dell'incidenza delle malattie croniche, aumenta anche la necessità di radiofarmaci, guidando così la crescita del mercato.
Approfondimenti basati sul tipo
In base al tipo, i radiofarmaci Il mercato è diviso in medicina nucleare diagnostica e medicina nucleare terapeutica. Il segmento della medicina nucleare diagnostica detiene una quota maggiore del mercato e si prevede che registrerà un CAGR più elevato nel periodo 2021-2028. Il radioisotopo ampiamente utilizzato nella medicina nucleare diagnostica è il tecnezio-99m. Il radioisotopo si lega a diverse molecole specifiche, consentendo la diagnosi di varie malattie, come alcuni tipi di cancro. Ad esempio, il tecnezio-99m-MDP (metilene difosfonato) è ampiamente utilizzato per rilevare metastasi ossee associate al cancro.
Approfondimenti basati sul tipo di prodotto
In base al tipo di prodotto, il mercato dei radiofarmaci è segmentato in tecnezio-99m, tallio-201, gallio-67 , Iodio-131, Rame-64 e altri. Il segmento del tecnezio-99m detiene la quota maggiore del mercato, mentre si prevede che il segmento del gallio-67 registrerà il CAGR più elevato nel periodo 2021-2028. Il gallio-67 viene utilizzato per l'imaging e la localizzazione di lesioni infiammatorie (infezioni). Il gallio-67 è un radiofarmaco iniettabile che viene utilizzato con la tomografia computerizzata a emissione di fotone singolo (SPECT) per rilevare la presenza di lesioni infiammatorie acute e varie neoplasie, come il morbo di Hodgkin, linfomi e carcinomi broncogeni.
Approfondimenti basati sull'applicazione
In base all'applicazione, il mercato dei radiofarmaci è segmentato in oncologia, cardiologia, neurologia e altri. Il segmento oncologico detiene la quota maggiore del mercato. La crescita del mercato per questo segmento può essere attribuita alla crescente incidenza del cancro in tutto il mondo. Il cancro è uno dei problemi sanitari più significativi con un alto tasso di mortalità. È una minaccia per la salute globale. Secondo l’OMS, nel 2018 sono stati diagnosticati circa 18 milioni di nuovi casi di cancro in tutto il mondo e 9,6 milioni di persone sono morte di cancro. Tuttavia, si prevede che il mercato per il segmento cardiologico crescerà al ritmo più rapido nei prossimi anni.
Approfondimenti basati sull'utente finale
Basati sull'utente finale , il mercato dei radiofarmaci è segmentato in ospedali, centri di imaging, centri accademici e di ricerca e altri. Nel 2021, il segmento ospedaliero detiene la quota maggiore del mercato. La crescita del mercato per questo segmento può essere attribuita alla crescente prevalenza di malattie croniche, al crescente numero di ospedali in tutto il mondo e al rapido aumento del numero di procedure chirurgiche. Tuttavia, si prevede che il mercato per il segmento dei centri diagnostici crescerà al ritmo più rapido nei prossimi anni.
Approfondimenti strategici
Le aziende che operano nel mercato dei radiofarmaci stanno adottando il strategia di innovazione dei prodotti per soddisfare le richieste in continua evoluzione dei clienti in tutto il mondo, che consente loro anche di mantenere il proprio marchio nel mercato globale.
Mercato dei radiofarmaci: per tipo
- Medicina nucleare diagnostica
- Radiofarmaci SPECT
- Radiofarmaci PET
- Nucleare terapeutico Medicina
- Emettitori alfa
- Emettitori beta
- Isotopi di brachiterapia
Mercato dei radiofarmaci - per tipo di prodotto
- Tecnezio-99m
- Tallio-201
- Gallio-67
- Iodio-131
- Rame-64
- Altro
Mercato dei radiofarmaci - per applicazione
- Oncologia
- Cardiologia
- Neurologia
- Altro
Mercato dei radiofarmaci – per utente finale
- Ospedali
- Centri di imaging
- Centri accademici e di ricerca
- Altro
Mercato dei radiofarmaci– per area geografica
- Nord America
- Stati Uniti
- Canada
- Messico
< li>Europa - Francia
- Germania
- Italia
- Regno Unito
- Spagna
- Resto dell'Europa
- Asia Pacifico (APAC)
- Cina
- India
- Corea del Sud
- Giappone
- Australia
- Resto dell'area APAC
- Medio Oriente e Africa (MEA)
- Sud Africa
- Arabia Saudita
- Emirati Arabi Uniti
- Resto del MEA
- America centrale e meridionale (SCAM )
- Brasile
- Argentina
- Resto di SCAM
Profili aziendali
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG < li>Bracco Imaging
- Prodotti nucleari Eczacýbaþý-Monrol
- Nordion
- Applicazioni di acceleratori avanzati
- Radioisotopi NTP
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.
The factors that are driving growth of the market are rising prevalence of chronic diseases, suitability of alpha radioimmunotherapy in targeted cancer treatment, and advancements in nuclear imaging techniques.
Various companies have made organic growth strategies in the Radiopharmaceuticals Market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Advanced Accelerator Applications amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.
North America dominates the global radiopharmaceuticals market due to factors such as technological advancement, increasing product launches, well-developed healthcare facility centres equipped with modern-age equipment and instruments.
The diagnostic nuclear medicine segment is growing at the highest CAGR owing to availability of diagnostic devices and ease offered by these devices for diagnosis of various disorders. Also, nuclear medicine provides better diagnostic information about the functioning of a specific organ, as it uses radiation.
Asia Pacific is expected to be the fastest growing region in the radiopharmaceuticals market. The growth of the market in this region is primarily due to prevalence of stroke and other neurological disorders along with the presence of supportive government initiatives and research in the field of radiopharmaceuticals.
The List of Companies - Radiopharmaceuticals Market
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG
- Bracco Imaging
- Eczacýbaþý-Monrol Nuclear Products
- Nordion
- Advanced Accelerator Applications
- NTP Radioisotopes
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)